An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
NCT06855706 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2026-01-06
Summary
This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II- IV ovarian, primary peritoneal, fallopian tube cancer or endometrial cancer that is newly diagnosed. Physical activity is a modifiable risk factor for the prevention and treatment of many diseases. In fact, increased levels of physical activity have been shown to decrease the risk of some cancers as well as increase overall survival in some cancers. Currently, standard of care guidelines include participation in at least 150 minutes of moderate exercise weekly. An automated personalized physical activity intervention may increase physical activity, enhance quality of life, and improve physical function and daily living activities compared to standard recommendations in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer. This trial also evaluates the impact of physical activity on the gut microbiome and immune function. The microbiome is the collection of tiny organisms, like bacteria, that live in and on the body, especially places like the gut. These microorganisms play an important role in health. Information gathered from this study may help understand how the gut microbiome and physical activity influences the immune system in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer.
Conditions
- Endometrial Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Stage II Fallopian Tube Cancer AJCC v8
- Stage II Ovarian Cancer AJCC v8
- Stage II Primary Peritoneal Cancer AJCC v8
- Stage III Fallopian Tube Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Primary Peritoneal Cancer AJCC v8
- Stage IV Fallopian Tube Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
- BEHAVIORAL
-
Behavioral Intervention
Receive personalized PA goals and positive feedback
- OTHER
-
Best Practice
Receive general PA counseling
- PROCEDURE
-
Biospecimen Collection
Undergo blood sample collection
- OTHER
-
Electronic Health Record Review
Ancillary studies
- OTHER
-
Exercise Intervention
Participate in MVPA
- OTHER
-
Medical Device Usage and Evaluation
Wear a Fitbit Sense 2 and CGM device
- OTHER
-
Questionnaire Administration
Ancillary studies
- OTHER
-
Supportive Care
Receive ongoing support
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Roswell Park Cancer Institute
lead OTHER
Principal Investigators
-
Emese Zsiros · Roswell Park Cancer Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-04
- Primary Completion
- 2027-04-30
- Completion
- 2028-04-30
Countries
- United States
Study Locations
More Related Trials
-
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
NCT03042897 ·Status: WITHDRAWN ·Phase: NA
-
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
NCT04701645 ·Status: RECRUITING ·Phase: PHASE1
-
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01080521 ·Status: COMPLETED
-
Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer
NCT02082470 ·Status: COMPLETED ·Phase: NA
-
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02839707 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02520154 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01167712 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
NCT05276973 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients
NCT02878980 ·Status: WITHDRAWN ·Phase: NA
-
Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies
NCT02578888 ·Status: COMPLETED ·Phase: NA
-
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
NCT02065687 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
NCT04214067 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
NCT00108745 ·Status: UNKNOWN ·Phase: PHASE3
-
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
NCT03029611 ·Status: TERMINATED ·Phase: PHASE2
-
Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer
NCT03297489 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
NCT04092270 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112 ·Status: RECRUITING ·Phase: PHASE3
-
Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers
NCT02412124 ·Status: TERMINATED ·Phase: NA
-
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02853318 ·Status: COMPLETED ·Phase: PHASE2
-
Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer
NCT00003794 ·Status: TERMINATED
-
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
NCT06710548 ·Status: RECRUITING ·Phase: NA
-
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT05691010 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00262847 ·Status: COMPLETED ·Phase: PHASE3
-
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
NCT01366183 ·Status: UNKNOWN